Veradermics, Incorporated

Stocks

MANE

US9229671048

Market Closed - NYSE 16:00:03 2026-09-18 EDT			5-day change	1st Jan Change
106.75 ^USD	-1.78%		+7.86%	-

09-09	Veradermics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03:00 PM
08-17	Veradermics Insider Sold Shares Worth $10,711,700, According to a Recent SEC Filing	MT

Transcript : Veradermics, Incorporated - Special Call

Published on 07/15/2026 at 10:21 am EDT - Modified on 07/20/2026 at 08:40 am EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, ladies and gentlemen, and welcome to Veradermics' conference call to discuss results from the female trial arms of Study 207, a Phase II

[

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Veradermics, Incorporated

09-09	Veradermics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03:00 PM
08-17	Veradermics Insider Sold Shares Worth $10,711,700, According to a Recent SEC Filing	MT
08-11	Veradermics, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-11	Veradermics' Q2 Net Loss Widens	MT
08-11	Earnings Flash (MANE) Veradermics Posts Q2 Net Loss $23.5M, vs. FactSet Est of $26.8M Loss	MT
08-02	20,000,170 Common Stock of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 3-AUG-2026.	CI
08-02	Certain Options of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 3-AUG-2026.	CI
07-28	Certain Stock Options of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 29-JUL-2026.	CI
07-28	14,570,076 Common Stock of Veradermics, Incorporated are subject to a Lock-Up Agreement Ending on 29-JUL-2026.	CI
07-17	Veradermics Announces Presentation of Data from Subgroup Analysis of Phase 2/3 Study ?302? in Males with Pattern Hair Loss	CI
07-15	Veradermics Shares Rise After Potential Female Hair Loss Treatment Restores Hair in Phase 2 Trial	MT
07-15	Veradermics, Incorporated Announces Positive Topline Results From Open-Label Phase 2 Clinical Trial Study 207 Evaluating VDPHL01 In Female Pattern Hair Loss	CI
07-15	Veradermics, Incorporated - Special Call
07-15	B. Riley Initiates Veradermics at Buy With $170 Price Target	MT
07-15	Veradermics' Potential Female Hair Loss Treatment Restores Hair in Phase 2 Trial	MT